Avalo Therapeutics (NASDAQ:AVTX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Avalo Therapeutics (NASDAQ:AVTX) from a hold rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.

Other research analysts have also issued reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Avalo Therapeutics in a report on Friday, July 24th. Guggenheim set a $48.00 price objective on shares of Avalo Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 7th. Weiss Ratings raised shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Leerink Partners assumed coverage on shares of Avalo Therapeutics in a research note on Monday, July 6th. They set an “outperform” rating and a $38.00 target price for the company. Finally, Bank of America initiated coverage on shares of Avalo Therapeutics in a report on Friday, June 12th. They issued a “buy” rating and a $35.00 price target for the company. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $45.10.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock opened at $16.12 on Friday. The business’s 50-day simple moving average is $19.07 and its 200-day simple moving average is $17.05. The firm has a market capitalization of $864.52 million, a PE ratio of -3.69 and a beta of 0.78. Avalo Therapeutics has a 52 week low of $9.54 and a 52 week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). Research analysts forecast that Avalo Therapeutics will post -2.69 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Christopher Sullivan sold 10,185 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $17.62, for a total value of $179,459.70. Following the completion of the transaction, the chief financial officer directly owned 39,900 shares of the company’s stock, valued at $703,038. This trade represents a 20.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the sale, the insider owned 51,776 shares in the company, valued at $931,968. This represents a 2.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 13,314 shares of company stock worth $239,140. 4.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Avalo Therapeutics

A number of hedge funds have recently made changes to their positions in AVTX. Geode Capital Management LLC boosted its position in shares of Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after acquiring an additional 2,648 shares in the last quarter. Nantahala Capital Management LLC raised its position in Avalo Therapeutics by 10.6% in the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock worth $4,965,000 after purchasing an additional 95,000 shares in the last quarter. Bank of America Corp DE raised its position in Avalo Therapeutics by 7,066.8% in the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock worth $2,029,000 after purchasing an additional 400,898 shares in the last quarter. Boothbay Fund Management LLC bought a new position in Avalo Therapeutics during the second quarter worth about $56,000. Finally, Vanguard Group Inc. boosted its holdings in Avalo Therapeutics by 314.9% during the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after purchasing an additional 525,696 shares in the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.